Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
Muñoz D, Escartín A, Dapena D, Coret F, Fernández-Uría D, Pérez D, Casanova B, Guijarro-Castro C, Munteis E, del-Campo Amigo M, Pego R, Calles C, García-Rey C, Monsalve N, Sánchez-Matienzo D. Muñoz D, et al. Among authors: calles c. BMC Neurol. 2013 Jul 11;13:82. doi: 10.1186/1471-2377-13-82. BMC Neurol. 2013. PMID: 23845043 Free PMC article.
Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.
Casanova B, Lacruz L, Villar ML, Domínguez JA, Gadea MC, Gascón F, Mallada J, Hervás D, Simó-Castelló M, Álvarez-Cermeño JC, Calles C, Olascoaga J, Ramió-Torrentà L, Alcalá C, Cervelló A, Boscá I, Pérez-Mirallles FC, Coret F. Casanova B, et al. Among authors: calles c. Neurol Sci. 2018 Aug;39(8):1423-1430. doi: 10.1007/s10072-018-3442-y. Epub 2018 Jun 7. Neurol Sci. 2018. PMID: 29882169
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
Toboso I, Tejeda-Velarde A, Alvarez-Lafuente R, Arroyo R, Hegen H, Deisenhammer F, Sainz de la Maza S, Alvarez-Cermeño JC, Izquierdo G, Paramo D, Oliva P, Casanova B, Agüera-Morales E, Franciotta D, Gastaldi M, Fernández O, Urbaneja P, Garcia-Dominguez JM, Romero F, Laroni A, Uccelli A, Perez-Sempere A, Saiz A, Blanco Y, Galimberti D, Scarpini E, Espejo C, Montalban X, Rasche L, Paul F, González I, Álvarez E, Ramo C, Caminero AB, Aladro Y, Calles C, Eguía P, Belenguer-Benavides A, Ramió-Torrentà L, Quintana E, Martínez-Rodríguez JE, Oterino A, López de Silanes C, Casanova LI, Landete L, Frederiksen J, Bsteh G, Mulero P, Comabella M, Hernández MA, Espiño M, Prieto JM, Pérez D, Otano M, Padilla F, García-Merino JA, Navarro L, Muriel A, Frossard LC, Villar LM. Toboso I, et al. Among authors: calles c. Front Neurol. 2020 Dec 17;11:579438. doi: 10.3389/fneur.2020.579438. eCollection 2020. Front Neurol. 2020. PMID: 33408681 Free PMC article.
Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis.
Castillo-Triviño T, Gómez-Ballesteros R, Borges M, Martín-Martínez J, Sotoca J, Alonso A, Caminero AB, Borrega L, Sánchez-Menoyo JL, Barrero-Hernández FJ, Calles C, Brieva L, Blasco-Quílez MR, García-Soto JD, Del Campo-Amigo M, Navarro-Cantó L, Agüera E, Garcés-Redondo M, Carmona O, Gabaldón-Torres L, Forero L, Hervás M, Mauriño J, Sainz de la Maza S. Castillo-Triviño T, et al. Among authors: calles c. Mult Scler Relat Disord. 2022 Aug;64:103969. doi: 10.1016/j.msard.2022.103969. Epub 2022 Jun 14. Mult Scler Relat Disord. 2022. PMID: 35728432 Free article.
Consensus on early detection of disease progression in patients with multiple sclerosis.
Meca-Lallana JE, Casanova B, Rodríguez-Antigüedad A, Eichau S, Izquierdo G, Durán C, Río J, Hernández MÁ, Calles C, Prieto-González JM, Ara JR, Uría DF, Costa-Frossard L, García-Merino A, Oreja-Guevara C. Meca-Lallana JE, et al. Among authors: calles c. Front Neurol. 2022 Jul 28;13:931014. doi: 10.3389/fneur.2022.931014. eCollection 2022. Front Neurol. 2022. PMID: 35968319 Free PMC article.
Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis.
Saposnik G, Andhavarapu S, Sainz de la Maza S, Castillo-Triviño T, Borges M, Barón BP, Sotoca J, Alonso A, Caminero AB, Borrega L, Sánchez-Menoyo JL, Barrero-Hernández FJ, Calles C, Brieva L, Blasco MR, García-Soto JD, Del Campo-Amigo M, Navarro-Cantó L, Agüera E, Garcés M, Carmona O, Gabaldón-Torres L, Forero L, Hervás M, García-Arcelay E, Terzaghi M, Gómez-Ballesteros R, Maurino J. Saposnik G, et al. Among authors: calles c. Mult Scler Relat Disord. 2022 Dec;68:104138. doi: 10.1016/j.msard.2022.104138. Epub 2022 Aug 20. Mult Scler Relat Disord. 2022. PMID: 36029707
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
Gascón-Giménez F, Alcalá C, Ramió-Torrentà L, Montero P, Matías-Guiu J, Gómez-Estevez I, Oreja-Guevara C, Gil-Perotín S, Blanco Y, Carcelén M, Quintanilla-Bordás C, Costa L, Villar LM, Martínez-Rodriguez JE, Domínguez JA, Calles C, González I, Sotoca J, Oterino A, Lucas-Jimenez C, Pérez-Miralles F, Casanova B. Gascón-Giménez F, et al. Among authors: calles c. Front Neurol. 2023 Mar 7;14:1060696. doi: 10.3389/fneur.2023.1060696. eCollection 2023. Front Neurol. 2023. PMID: 36959824 Free PMC article.
Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach.
Sainz de la Maza S, Gómez-Ballesteros R, Borges M, Martín-Martínez J, Sotoca J, Alonso A, Caminero AB, Borrega L, Sánchez-Menoyo JL, Barrero-Hernández FJ, Calles C, Brieva L, Blasco-Quílez MR, Dotor García-Soto J, Del Campo-Amigo M, Navarro-Cantó L, Agüera E, Garcés-Redondo M, Carmona O, Gabaldón-Torres L, Forero L, Hervàs M, Medrano N, Maurino J, Castillo-Triviño T. Sainz de la Maza S, et al. Among authors: calles c. Mult Scler J Exp Transl Clin. 2023 May 10;9(2):20552173231169475. doi: 10.1177/20552173231169475. eCollection 2023 Apr-Jun. Mult Scler J Exp Transl Clin. 2023. PMID: 37187856 Free PMC article.
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE, Prieto González JM, Caminero Rodríguez AB, Olascoaga Urtaza J, Alonso AM, Durán Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Pérez Ruiz D, Calles C, Hernández MA, Hervás García M, Mendoza Rodríguez A, Berdei Montero Y, Téllez N, Herrera Varó N, Sotoca J, Presas-Rodríguez S, Querol Gutierrez LA, Hervás Pujol M, Batlle Nadal J, Martín Ozaeta G, Gubieras Lillo L, Martínez Yélamos S, Ramió-Torrentà L, Mallada Frechin J, Belenguer Benavides A, Gascón-Giménez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gómez Gutierrez M, Durán C, Rodríguez Regal A, Álvarez E, García-Estévez DA, López Real AM, Llaneza González MA, Marzo Sola ME, Sánchez-Menoyo JL, Oterino A, Villaverde González R, Castillo-Triviño T, Álvarez de Arcaya A, Llarena C. Meca-Lallana JE, et al. Among authors: calles c. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. Neurol Ther. 2023. PMID: 37861931 Free PMC article.
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.
Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, de Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A. Sepúlveda M, et al. Among authors: calles c. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225. doi: 10.1212/NXI.0000000000000225. eCollection 2016 Jun. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27144216 Free PMC article.
49 results